Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2021 08:30 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Completes CMC and GLP Production for THCVHS Lead Program

Novel glaucoma drug ready for next development phase - GLP toxicology study – on critical path to first human clinical trialOngoing development of THCVHS includes near-term preclinical comparison with...
April 15, 2021 08:45 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Present at Upcoming Investment Conferences in April

San Diego, Calif, April 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
March 18, 2021 08:45 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Present at Benzinga Biotech Small Cap Conference

San Diego, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
March 16, 2021 08:30 ET | Source: Skye Bioscience, Inc.

Skye Bioscience’s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment

San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
March 08, 2021 08:39 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board

San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
March 03, 2021 08:37 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference

San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
February 03, 2021 09:09 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Participate in Investment Conferences in February

San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
January 19, 2021 08:30 ET | Source: Skye Bioscience, Inc.

Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience

San Diego, Calif, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
January 15, 2021 13:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience to Change Name and Trading Symbol Effective Tuesday, January 19th

San Diego, Calif, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI” or the “Company”), a biopharmaceutical company focused on developing proprietary,...
January 05, 2021 08:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience to Present at the KCSA Cannabis Investor Conference

San Diego, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, proprietary...